Zerilli et al. suggested a strategy for overcoming upregulated HIF1-α expression by administering sorafenib, which could block BRAFV600E and its downstream in BRAFV600E-mutated thyroid cancers [49]. This evidence concerns the gene HIF1A and thyroid cancer.